What the FDA labels say about taking them together
Drospirenone/ethinyl estradiol/levomefolate and ritonavir
Drospirenone/ethinyl estradiol/levomefolate's FDA label of March 4, 2026 names ritonavir in its contraindications section; the ritonavir label PlainMeds reads does not name drospirenone/ethinyl estradiol/levomefolate. The drospirenone/ethinyl estradiol/levomefolate label: “Use with HCV Combination Therapy – Liver Enzyme Elevation Do not co-administer Beyaz with HCV drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to potential for ALT …”
Check it at the source: the drospirenone/ethinyl estradiol/levomefolate FDA label on DailyMed (effective March 4, 2026, Bayer HealthCare Pharmaceuticals Inc.); the ritonavir FDA label on DailyMed (effective July 23, 2026, AbbVie Inc.).
What does the drospirenone/ethinyl estradiol/levomefolate label say about ritonavir?
Drospirenone/ethinyl estradiol/levomefolate label, contraindicationsUse of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir due to the potential for ALT elevations [see Warnings and Precautions ( 5.5 ) and Drug Interactions ( 7.3 )].
Drospirenone/ethinyl estradiol/levomefolate label, drug interactionsUse with HCV Combination Therapy – Liver Enzyme Elevation Do not co-administer Safyral with HCV drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to potential for ALT elevations [see Warnings and Precautions ( 5.5 )].
Drospirenone/ethinyl estradiol/levomefolate label, warnings and precautionsElevations with Concomitant Hepatitis C Treatment During clinical trials with the Hepatitis C combination drug regimen that contains ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, ALT elevations greater than 5 times the upper limit of normal (ULN), including some cases greater than 20 times the ULN, were significantly more frequent in women using ethinyl estradiol-containing medications, such as COCs.
Source: FDA drug label (Beyaz, NDA022532), Bayer HealthCare Pharmaceuticals Inc., effective March 2, 2026 (SPL set 8132454a-6135-4bac-b206-83a55eb8dbc6), via openFDA
Source: FDA drug label (Safyral), Bayer HealthCare Pharmaceuticals Inc., effective March 4, 2026 (SPL set 97563516-306a-4e17-9690-edbda49ecd83), via openFDA; the full label on DailyMed
What does the ritonavir label say about drospirenone/ethinyl estradiol/levomefolate?
Ritonavir's label (effective July 23, 2026) does not name drospirenone/ethinyl estradiol/levomefolate in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Norvir), AbbVie Inc., effective July 23, 2026 (SPL set 2849298e-de6e-47bb-8194-56e075b33fc3), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Drospirenone/ethinyl estradiol/levomefolate | Ritonavir | |
|---|---|---|
| Labeled for | Birth control, Acne | HIV |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $1.38 per unit 3-0.02-0.451 | $0.607 per tablet 100 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once